
The FDA approves Bildyos and Bilprevda, expanding treatment options for osteoporosis and cancer-related bone loss, enhancing patient access and affordability.

The FDA approves Bildyos and Bilprevda, expanding treatment options for osteoporosis and cancer-related bone loss, enhancing patient access and affordability.

Zongertinib receives FDA breakthrough therapy designation for treating HER2-mutant non-small cell lung cancer, promising new hope for patients.

The IOS-202/azacitidine combination revealed a complete response of 27.8% and an overall response rate of 66.7% in patients with chronic myelomonocytic leukemia.

A new triple therapy shows promising results for treating BRAF V600E-mutant metastatic colorectal cancer, significantly improving patient outcomes.

Zymeworks discontinues ZW171 clinical development after phase 1 trial reveals unfavorable benefit-risk profile, shifting focus to other promising candidates.

August 2025 marked a transformative month in oncology as the FDA accelerates approvals for innovative cancer therapies, enhancing treatment options for patients.

This week in oncology highlights breakthroughs in cancer diagnostics and therapies, offering new hope for patients with colorectal, brain, ovarian, and breast cancers.

New clinical trial results reveal annamycin's promise in treating relapsed AML, showing improved survival rates and a favorable safety profile.

The FDA approves a long-acting injectable for advanced prostate cancer, offering a convenient quarterly dosing option and improved patient care.

Sonrotoclax shows promise as a new treatment for relapsed/refractory mantle cell lymphoma, achieving significant response rates in heavily pretreated patients.

Abemaciclib significantly enhances survival rates in high-risk early breast cancer, establishing its role as a standard treatment alongside endocrine therapy.

A groundbreaking study reveals how the Decipher Prostate Genomic Classifier personalizes chemotherapy decisions for metastatic prostate cancer patients, enhancing treatment outcomes.

With pegtarazimod and belumosudil advancing through the global pipeline, options are expanding for patients with GVHD worldwide.

VGT-1849B receives FDA orphan drug designation, promising a targeted treatment for polycythemia vera with improved safety and efficacy.

New research identifies low counts of activated HLA-DR+CD3+ T cells as a potential biomarker for increased transplant-related mortality and severe chronic graft-versus-host disease.

TT125-802, a promising bromodomain inhibitor, gains FDA fast track status for treating advanced non-small cell lung cancer, addressing critical patient needs.

FDA reviews gedatolisib for advanced breast cancer, showing significant progression-free survival improvements in pivotal VIKTORIA-1 trial.

The European Commission approves tislelizumab for neoadjuvant treatment of resectable NSCLC, enhancing survival rates and offering new hope for patients.

High Ki-67 expression predicts poorer survival in patients with acral melanoma, a rare subtype in which Ki-67's predictive value had not been established.

A pivotal trial evaluates patritumab deruxtecan for advanced HR-positive, HER2-negative breast cancer, offering hope for patients after standard therapies.

A novel assay identifies low-risk patients with high-risk ER+/HER2– early breast cancer, potentially sparing them from unnecessary treatment escalation.

New studies reveal how the DecisionDx-SCC test enhances treatment decisions for high-risk cutaneous squamous cell carcinoma, improving patient outcomes.

In a pilot study, a novel regimen showed 100% disease control in 5 patients with recurrent GBM, with 2 achieving near complete response.

FDA breakthrough therapy designation granted for rinatabart sesutecan in endometrial cancer, based on encouraging data from a phase 1/2 trial.

Final data from the VERSATILE-002 trial for HPV16-positive HNSCC shows a median overall survival of 39.3 months with PDS0101 plus pembrolizumab.

Incorporating molecular classification into preoperative staging for endometrial cancer improved risk stratification in patients with high-risk endometrial cancer.

The FDA has granted breakthrough device designation to the Haystack MRD test, a circulating tumor DNA (ctDNA) test, for use in patients with stage II colorectal cancer following surgery.

Innovent's bispecific antibody, IBI363, enters a global phase 3 trial for IO-resistant lung cancer, the first of its kind, offering new hope for this patient group.

Catch up with the latest in oncology news from this week with this edition of The Targeted Pulse.

A trade agreement between the US and EU sets a 15% tariff on most European pharma imports, impacting oncology drug supplies and potentially costing the industry billions.